Dr Angray Kang, BSc (Hons), PhD
Reader in Molecular Cell Biology
Email: firstname.lastname@example.orgTelephone: +44 (0) 20 7882 7158Room Number: Blizard Building
1979-83 Kings (Chelsea College) University of London B.Sc. Microbiology 1st Class Honours.
1983-86 University of East Anglia Ph.D. Biochemistry (Institute of Food Research Norwich, supervisor Prof. Henry W-S. Chan). The research was supported by an AFRC studentship and directed towards generating antibodies against mycotoxins (aflatoxin & sterigmatocystin) and developing non-isotopic immunoassays.
1986-87 Post doctoral research (SERC) at University of Durham UK with Professor Don Boulter.
1987-89 Post doctoral research (SERC) at University of Sheffield UK with Professor Dennis Burton.
1989-90 Visiting post doctoral researcher at The Scripps Research Institute with Professor Richard A. Lerner.
1990-1999 Assistant Professor Molecular Biology, The Scripps Research Institute.
Between 1999 and the return to academia in 2005 held various posts of increasing responsibility in drug discovery and development in biopharmaceutical companies (Abgenix Inc, Diversa Corporation and Avanir Pharmaceuticals).
2005-2011 Reader in Molecular Applied Biosciences at the University of Westminster.
2011- present Reader in Molecular Cell Biology Queen Mary University of London.
Google Scholar Citations
Achievements in education
Awarded Fellowship of the Higher Education Authority. Supervised PhD, DClinDent, MSc , BSc, iBSc, FY1 and FY2 project students. Developed and rolled out a novel approach to engage students in research via the SSC component in the new BDS curriculum. Participated in delivery of BDS Yr1 (Basic Sciences)and Yr3 (SSC) , MSc Oral Biology and MSc EOP MSc. Introduced lectures on the potential of therapeutic use of antibodies in dentistry. Co-developed a module with Prof Gareth Sanger on Drug Discovery and Development for the Yr3 BSc Biomedical Sciences. Active internal PhD progression panel member for PhD students across SMD and SBCS.
Vaccination offers protection against many pathogens, but it is increasingly recognized that towards the end of the the 20th century, successes of the past may be difficult to attain for all pathogens. Viruses which are highly mutable such as HIV-1 and HCV, to date have proved difficult "moving" targets. In other cases vaccines may be effective but the timelines required to build up immunity are long as is the case with anthrax vaccine adsorbed (AVA). Parasites such as Plasmodium falciparum and Trypanosoma cruzi, the causative agents of malaria and Chagas' disease respectively, have also proved to be challenging targets for vaccine development.
An alternative approach is to look at individuals exposed to either the pathogen or a vaccine and decipher the antibody response and to attempt to identify what may be protective antibodies for use in passive immunisation or to aid the design of vaccines based on conserved protective structures or even use the genetically encoded antibodies in novel interventions.
In order to do undertake such molecular dissection of the antibody response requires the development and application of enabling molecular display technologies.
Real achievements in research
- Development of transgenic fungi that kill human malaria parasites in mosquitoes. Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Science. 2011 Feb 25;331(6020):1074-7
- A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, Teyton L. Science. 2000 Apr 21;288(5465):505-11.
- Antibodies without immunization. Lerner RA, Kang AS, Bain JD, Burton DR, Barbas CF 3rd. Science. 1992 Nov 20;258(5086):1313-4.
- Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda.Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Science. 1989 Dec 8;246(4935):1275-81.
- Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Barbas CF 3rd, Kang AS, Lerner RA, Benkovic SJ. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7978-82
- Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2475-80.
- Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Kang AS, Jones TM, Burton DR. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11120-3.
- Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4363-6.
- In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Gram H, Marconi LA, Barbas CF 3rd, Collet TA, Lerner RA, Kang AS. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3576-80.
- On the use of combinatorial antibody libraries to clone the "fossil record" of an individual's immune response. Lerner RA, Barbas CF 3rd, Kang AS, Burton DR. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9705-6.
- Propagation of an attenuated virus by design: engineering a novel receptor for a noninfectious foot-and-mouth disease virus. Rieder E, Berinstein A, Baxt B, Kang A, Mason PW. Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10428-33.
4 Science article (4 is a citation classic)
7 PNAS articles
16 Issued US patents.
The best-selling drug globally in 2016 and 2017 was Humira (Adalimumab) with sales of US$14 and 17 Billion respectively. It was discovered using a range of technologies pioneered in the publications above, from combinatorial antibody library technology4, phagemid based Fab phage display5,8 and combining accessing naive antibody libraries9 with chain shuffling7. The technologies described in the publication also led to patent fillings. The patents were acquired by Johnson & Johnson and licenced to other biopharma companies for drug discovery.
Tang J, Wang L, Markiv A, Jeffs SA, Dreja H, McKnight A, He M, Kang AS. Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Human Antibodies. 2012 in press.
Azizi A, Arora A, Markiv A, Lampe DJ, Miller T, Kang AS. Ribosome Display of Combinatorial Antibody Libraries Derived From Mice Immunised With Heat-Killed Xylella fastidiosa and the Selection of MopB-Specific Single-Chain Antibodies. Appl Environ Microbiol. 2012 Apr;78(8):2638-47.
Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS. Expression of recombinant multi-coloured fluorescent antibodies in gor -/ trxB- E. coli cytoplasm. BMC Biotechnol. 2011 Nov 30;11(1):117.
Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science. 2011 Feb 25;331(6020):1074-7.
Markiv A, Anani B, Durvasula RV, Kang AS. Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods. 2011 Feb 1;364(1-2):40-9.
Achievements in leadership
Led on the development of a new SSC format for BDS. Led on the development of a novel Anti-Antibody Drug Assay to be used across SMD
Achievements in administration support
Administer SSC as lead , MSc EOP as lead. Assisted in BDS intake interviews